Biogen Inc. (NASDAQ:BIIB) is one of the best defensive stocks to buy, according to Steve Cohen. On September 5, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $194 price target. The positive stance echoes the research firm’s confidence about the company’s promising lupus franchise. H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects According to H.C. Wainwright, the lupus treatments litifilimab and dapirolizumab pegol are compelling late-stage assets that unde ...